UCB SA (UCBJF)
USD 195.88
(0.0%)
USD 195.88
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.17 Billion EUR | 8.8% |
| 2022 | 2 Billion EUR | 132.67% |
| 2021 | 860 Million EUR | -39.05% |
| 2020 | 1.41 Billion EUR | 20257.14% |
| 2019 | -7 Million EUR | -102.95% |
| 2018 | 237 Million EUR | -54.77% |
| 2017 | 524 Million EUR | -37.62% |
| 2016 | 840 Million EUR | -8.99% |
| 2015 | 923 Million EUR | -42.78% |
| 2014 | 1.61 Billion EUR | -19.75% |
| 2013 | 2.01 Billion EUR | 13.62% |
| 2012 | 1.76 Billion EUR | 14.13% |
| 2011 | 1.55 Billion EUR | -1.4% |
| 2010 | 1.57 Billion EUR | -10.53% |
| 2009 | 1.75 Billion EUR | -28.29% |
| 2008 | 2.45 Billion EUR | 26.22% |
| 2007 | 1.94 Billion EUR | -9.3% |
| 2006 | 2.14 Billion EUR | 239.14% |
| 2005 | 631 Million EUR | -69.51% |
| 2004 | 2.06 Billion EUR | 4905.76% |
| 2003 | -43.06 Million EUR | 81.5% |
| 2002 | -232.69 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 2.41 Billion EUR | 2.15% |
| 2024 Q1 | 2.55 Billion EUR | 17.36% |
| 2023 Q2 | 2.43 Billion EUR | 2.01% |
| 2023 FY | 2.17 Billion EUR | 8.8% |
| 2023 Q3 | 2.13 Billion EUR | -12.51% |
| 2023 Q4 | 2.17 Billion EUR | 2.01% |
| 2023 Q1 | 2.39 Billion EUR | 19.49% |
| 2022 Q2 | 2.5 Billion EUR | 1.91% |
| 2022 Q4 | 2 Billion EUR | 2.04% |
| 2022 FY | 2 Billion EUR | 132.67% |
| 2022 Q1 | 2.45 Billion EUR | 185.47% |
| 2022 Q3 | 1.96 Billion EUR | -21.62% |
| 2021 Q1 | 1.47 Billion EUR | 4.82% |
| 2021 Q2 | 1.51 Billion EUR | 2.37% |
| 2021 Q4 | 860 Million EUR | 4.37% |
| 2021 Q3 | 824 Million EUR | -45.57% |
| 2021 FY | 860 Million EUR | -39.05% |
| 2020 Q4 | 1.41 Billion EUR | 2.54% |
| 2020 Q1 | 1.88 Billion EUR | 26957.14% |
| 2020 Q3 | 1.37 Billion EUR | -28.15% |
| 2020 FY | 1.41 Billion EUR | 20257.14% |
| 2020 Q2 | 1.91 Billion EUR | 1.86% |
| 2019 Q3 | -50 Million EUR | -112.92% |
| 2019 FY | -7 Million EUR | -102.95% |
| 2019 Q1 | 348 Million EUR | 46.84% |
| 2019 Q2 | 387 Million EUR | 11.21% |
| 2019 Q4 | -7 Million EUR | 86.0% |
| 2018 Q3 | 199 Million EUR | -74.26% |
| 2018 Q1 | 738 Million EUR | 40.84% |
| 2018 FY | 237 Million EUR | -54.77% |
| 2018 Q4 | 237 Million EUR | 19.1% |
| 2018 Q2 | 773 Million EUR | 4.74% |
| 2017 Q2 | 988 Million EUR | 0.2% |
| 2017 Q3 | 522 Million EUR | -47.17% |
| 2017 Q4 | 524 Million EUR | 0.38% |
| 2017 FY | 524 Million EUR | -37.62% |
| 2017 Q1 | 986 Million EUR | 17.38% |
| 2016 Q1 | 1.34 Billion EUR | 45.83% |
| 2016 FY | 840 Million EUR | -8.99% |
| 2016 Q4 | 840 Million EUR | -7.49% |
| 2016 Q3 | 908 Million EUR | -32.64% |
| 2016 Q2 | 1.34 Billion EUR | 0.15% |
| 2015 Q1 | 1.81 Billion EUR | 12.59% |
| 2015 Q3 | 1.09 Billion EUR | -39.48% |
| 2015 FY | 923 Million EUR | -42.78% |
| 2015 Q4 | 923 Million EUR | -16.01% |
| 2015 Q2 | 1.81 Billion EUR | 0.0% |
| 2014 Q2 | 1.73 Billion EUR | 0.12% |
| 2014 Q1 | 1.72 Billion EUR | -14.03% |
| 2014 FY | 1.61 Billion EUR | -19.75% |
| 2014 Q4 | 1.61 Billion EUR | 0.25% |
| 2014 Q3 | 1.6 Billion EUR | -6.99% |
| 2013 Q2 | 2.09 Billion EUR | 0.0% |
| 2013 Q1 | 2.09 Billion EUR | 18.6% |
| 2013 Q4 | 2.01 Billion EUR | 0.65% |
| 2013 FY | 2.01 Billion EUR | 13.62% |
| 2013 Q3 | 1.99 Billion EUR | -4.81% |
| 2012 FY | 1.76 Billion EUR | 14.13% |
| 2012 Q2 | 1.76 Billion EUR | 0.0% |
| 2012 Q4 | 1.76 Billion EUR | 0.0% |
| 2011 Q4 | 1.55 Billion EUR | 0.0% |
| 2011 Q2 | 1.42 Billion EUR | 0.0% |
| 2011 FY | 1.55 Billion EUR | -1.4% |
| 2010 Q4 | 1.57 Billion EUR | 0.0% |
| 2010 FY | 1.57 Billion EUR | -10.53% |
| 2010 Q2 | 1.87 Billion EUR | 0.0% |
| 2009 Q4 | 1.75 Billion EUR | 0.0% |
| 2009 FY | 1.75 Billion EUR | -28.29% |
| 2008 FY | 2.45 Billion EUR | 26.22% |
| 2007 FY | 1.94 Billion EUR | -9.3% |
| 2006 FY | 2.14 Billion EUR | 239.14% |
| 2005 FY | 631 Million EUR | -69.51% |
| 2004 FY | 2.06 Billion EUR | 4905.76% |
| 2003 FY | -43.06 Million EUR | 81.5% |
| 2002 FY | -232.69 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | -13710.823% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -52765.161% |
| SQZ Biotechnologies Company | -36.23 Million USD | 6107.506% |
| Evofem Biosciences, Inc. | 42.79 Million USD | -4987.281% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 34630.759% |
| Mesoblast Limited | 55.85 Million USD | -3797.365% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -234696.47% |
| Genus plc | 190.6 Million USD | -1042.183% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -97268.675% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -179241.092% |
| Marizyme, Inc. | 18.56 Million USD | -11623.823% |
| ContraFect Corporation | -6.02 Million USD | 36226.784% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -320047.059% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -1616816.347% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -188314.866% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -96990.713% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -39468.178% |
| MultiCell Technologies, Inc. | 90.04 USD | -2417814204.753% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 296702.895% |
| RVL Pharmaceuticals plc | 12.94 Million USD | -16716.005% |
| EV Biologics, Inc. | 1.36 Million USD | -159040.8% |
| Q BioMed Inc. | 4.06 Million USD | -53520.584% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | -7025.09% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -349695.297% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -215933.089% |
| Biomind Labs Inc. | 711.4 Thousand USD | -305915.446% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 109.8 Million USD | -1882.624% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | -16899.061% |
| Skye Bioscience, Inc. | -5.72 Million USD | 38150.201% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -252968.617% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -1557080.052% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -38442.093% |
| IMV Inc. | 7.67 Million USD | -28281.384% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -10957769.834% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -98765.522% |
| GB Sciences, Inc. | 1.74 Million USD | -124491.087% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 1184616.943% |
| HST Global, Inc. | 96.79 Thousand USD | -2249029.586% |
| CSL Limited | 10.52 Billion USD | 79.318% |
| Halberd Corporation | 144.72 Thousand USD | -1504173.741% |
| Enzolytics Inc. | 981.65 Thousand USD | -221668.114% |
| Resverlogix Corp. | 6.45 Million USD | -33646.706% |
| Affymax, Inc. | -5.59 Million USD | 38995.837% |
| SYBLEU INC | 473.71 Thousand USD | -459459.988% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 323534.197% |
| argenx SE | -2.02 Billion USD | 207.302% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | -4912.202% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 4730.733% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -80273.18% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 24726.942% |
| AVAX Technologies, Inc. | -5.9 Million USD | 36978.26% |
| Zenith Capital Corp. | 10.06 Thousand USD | -21631458.029% |
| Genscript Biotech Corporation | -1.06 Billion USD | 305.119% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -1086053.908% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -91139.27% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -1323231.854% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | -3495.628% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -108783.1% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | 84807.116% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -605109.752% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | -10636.832% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 11884585.206% |
| BioStem Technologies, Inc. | 4.47 Million USD | -48580.56% |
| ONE Bio Corp. | 9.04 Million USD | -23981.765% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -1081617.63% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 166183306.107% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -1055584.061% |
| Agentix Corp. | 37.63 Thousand USD | -5785023.967% |
| LadRx Corporation | -2.03 Million USD | 107000.719% |
| Cell Source, Inc. | 9.23 Million USD | -23481.097% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 10667485.339% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -342644.507% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -342644.507% |
| NovAccess Global Inc. | 2.17 Million USD | -99832.751% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -30687.846% |
| Itoco Inc. | 228.3 Thousand USD | -953448.981% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -1600764.776% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -43817.692% |
| Kadimastem Ltd | -253.1 Thousand USD | 860227.538% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -541645.78% |
| CytoDyn Inc. | 20.26 Million USD | -10644.25% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 336476143.277% |
| Mobile Lads Corp. | 484.23 Thousand USD | -449477.888% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 23488664.295% |
| Qrons Inc. | 351.42 Thousand USD | -619374.315% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -28150.706% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 872225.631% |
| Rebus Holdings, Inc. | 305 Thousand USD | -713670.492% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -48744.273% |
| International Stem Cell Corporation | 2.59 Million USD | -83954.054% |
| Bioxytran, Inc. | 1.89 Million USD | -114544.476% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -3487955.373% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -99721.175% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -63295.457% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -25353.057% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -281673.269% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 174260.0% |
| Neutra Corp. | 52.18 Thousand USD | -4171436.973% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 87564.845% |
| PureTech Health plc | -167.19 Million USD | 1402.057% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 889005.222% |
| IXICO plc | -4.44 Million USD | 49080.929% |
| IntelGenx Technologies Corp. | 13.21 Million USD | -16368.719% |
| Gelesis Holdings, Inc. | 54.85 Million USD | -3868.934% |
| CSL Limited | 10.52 Billion USD | 79.318% |
| Cellectis S.A. | -43.81 Million USD | 5068.179% |